Date:			6/23/2023		
Your Name:			James E Galvin, MD, MPH		
Manuscript Title:			Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset		
Mar	nuscript Number (if k	(nown):	N/A		
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activiti		ipt. "Rela of the man e in doubt os/activition, you	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be inuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so. dies/interests should be defined broadly. For example, if your manuscript pertains to the bushould declare all relationships with manufacturers of antihypertensive medication, even if lin the manuscript.		
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
				of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		one	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for			Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		one	Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Nationa No.	Time frame: past 36 month	Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Alpha Cognition Biogen Cognivue Eisai Eli Lilly Genentech GE Healthcare Roche None	Me Me Me Me Me Me Me
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None PassageBio	Me
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Lewy Body Dementia Association Lewy Body Dementia Resource Center SE Florida Chapter of Alzheimer Association	Board of Directors (unpaid) Board of Directors (unpaid) Board of Directors (unpaid)

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Cognivue	Stock options – no payment
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:		12/5/2023			
You	r Name:	Jeffrey Cummings	Jeffrey Cummings		
Manuscript Title:		Generating real-world evidence in Alzheime dataset	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset		
Mar	nuscript Number (if k	known): ADJ-D-23-00856			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activiti		ript. "Related" means any relation with for-profit or no of the manuscript. Disclosure represents a commitme re in doubt about whether to list a relationship/activity ps/activities/interests should be defined broadly. For e ension, you should declare all relationships with manuf	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be inuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so. ies/interests should be defined broadly. For example, if your manuscript pertains to the should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	em #1 below, report ne for disclosure is th	all support for the work reported in this manuscript we past 36 months.	ithout time limit. For all other items, the time		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIGMS grant: P20GM109025; NIA grants: R01AG053798, P20AG068053, R35AG71476; NINDS grant U01NS093334	Click the tab key to add additional rows.		
		Time frame: past 36 month	S		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	□ None Ownership of Neuropsychiatric Inventory (NPI)			

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	AB Science, Acadia, Alkahest, AlphaCognition, ALZPath, Annovis, AriBio, Artery, Avanir, Biogen, Biosplice, Cassava, Cerevel, Clinilabs, Cortexyme, Diadem, EIP Pharma, Eisai, GatehouseBio, GemVax, Genentech, Green Valley, Grifols, Janssen, Karuna, Lexeo, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Otsuka, PharmacotrophiX, PRODEO, Prothena, ReMYND, Renew, Resverlogix, Roche, Signant Health, Suven, Unlearn AI, Vaxxinity, VigilNeuro, Zai Laboratories pharmaceutical, assessment, and investment companies.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	ADAMAS, Acumen, Alkahest, Alzheon, AnnovisBio, Behren Therapeutics, BIOasis, MedAvante, and United Neuroscience	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ □	
13	Other financial or non-financial interests	Chief Scientific Advisor – CNS Innovations, LLC.	
Plea [⊠]		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

e:	Dec 7th, 2023
r Name:	Mihaela Levitchi Benea
nuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
nuscript Number (if l	wn): _ADJ-D-23-00856
tent of your manuscr cted by the content	ncy, we ask you to disclose all relationships/activities/interests listed below that are related to the . "Related" means any relation with for-profit or not-for-profit third parties whose interests may be the manuscript. Disclosure represents a commitment to transparency and does not necessarily a doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
lemiology of hyperte	activities/interests should be defined broadly. For example, if your manuscript pertains to the on, you should declare all relationships with manufacturers of antihypertensive medication, even if tioned in the manuscript.
	support for the work reported in this manuscript without time limit. For all other items, the time past 36 months.
	ame all entities with whom you have this Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work
All support for the present manuscript (e.g., funding, provision of study	Trom Sept 2014-June 2022
•	Click the tab key to add additional rows.
processing charges, etc.) No time limit for this item.	Click the tab key to add additional rows.
	Time frame: past 36 months
Grants or contracts from any entity (if not indicated in item	□ X None
#1 above).	
Royalties or	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ X None	
6	Payment for expert testimony	□ X None	
7	Support for attending meetings and/or travel	□ X None	
8	Patents planned, issued or pending	□ X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None I owed Biogen stock	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ X None	
13	Other financial or non-financial interests	□ X None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	12/19/2023
Your Name:	Carl de Moor
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None I was a former staff member of Biogen when	ras a former staff member of Biogen when this manuscript was initiated	
			Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Х	None		
3	Royalties or licenses	X	None		

			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X	None	
6	Payment for expert testimony	X	None	
7	Support for attending meetings and/or travel	X	None	
8	Patents planned, issued or pending	X	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X	None	

			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X	None	
11	Stock or stock options		None As a former staff member of Biogen, I held Bi	ogen stock.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X	None	
13	Other financial or non-financial interests	X	None	
Dlos				
	lease place an "X" next to the following statement to indicate your agreement:			
Χ	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/28/2023
Your Name:	Ricardo F Allegri
Manuscript Title:	[Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	1/8/2024
Your Name:	Alireza Atri, MD, PhD
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item	None	Site PI for biopharma-sponsored clinical trials
	#1 above).	Alzheon, Athira Biohaven (with ADCS), Eisai (with ATRI/ACTC), Lilly (with ATRI/ACTC), Vivoryon (with ADCS) ACTC, ADCS, AZ Alzheimer's Research Consortium and AZ DHS, ATRI, GAP USC, Indiana Univ, Johns Hopkins Washington University St. Louis	at institution Site PI for biopharma-AD consortium collaborative sponsored clinical trials at institution Site PI for clinical trials sponsored or cosponsored or grants from Research Consortia or Institutes Site PI for collaborative clinical trials sponsored or cosponsored by Universities Project Arm Leader for international clinical trial

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Gates Ventures	Grant from Foundation
		AZ DHS, NIA/NIH	Grants from state or federal agency
			PI for Single Site Biomarker (SV2A-PET) study
		Foundation for NIH (FNIH)	funded by FNIH
3	Royalties or licenses	☐ None	
		Oxford University Press	Book on dementia
4	Consulting fees	□ None	
		Lundbeck	Current
		Novo Nordisk	Current
		Eisai	Current
		Prothena	Current
		Acadia	Past/completed
		AZ Therapies	Past/completed
		Biogen	Past/completed
		JOMDD	Past/completed
		Roche/Genetech	Past/completed
		Qynapse	Past/completed
		Merck	Past/completed
5	Payment or honoraria for	□ None	
	lectures,	Acadia,	_ ,
	presentations,	Biogen,	Past/completed;
	speakers	Eisai,	No speakers bureaus; No payments for
	bureaus, manuscript	Lundbeck	manuscript writing
	writing or		
	educational		
	events		
6	Payment for expert testimony	[⊠] None	
7	Support for attending		
	meetings and/or	Alzheimer's Association (US),	
	travel	Alzheimer's Disease International (ADI),	Only for consulting mtgs, scientific/medical
		American Academy of Neurology (AAN)	presentations or educational programs
			. 5

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Roche/Genentech	Past/completed
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
	Please place an "X" next to the following statement to indicate your agreement:		
\boxtimes	i certify that I have	answered every question and have not altered the wo	raing of any of the questions on this form.

Date:	Click or tap to enter a date.
Your Name:	Howard Chertkow
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856
In the interest of transparency, w	e ask you to disclose all relationships/activities/interests listed below that are related to the

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None See attached list Conflict of Interest Dr. Chertkow is supported by grants from the CIHR (Canadian Institutes for Health Research), NIH (National Institute of Health, USA), along with the Weston Foundation and the Baycrest Health Sciences Foundation. Dr. Chertkow has participated as a site PI in pharmaceutical trial activities in the past five years sponsored by: Hoffmann-La Roche Limited, TauRx, Lilly,	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Anavex Life Sciences, Alector LLC, Biogen, and Immunocal (site investigator for trials). Dr. Chertkow has participated as an unpaid advisor in 2020 for establishment of an international database by Biogen. Dr. Chertkow has received honoraria for sitting on advisory boards for Eisai and Lilly in Canada. Dr. Chertkow is Scientific Director for the CCNA, which receives partner support from a set of partners including not for profit organizations: Brain Canada, Alzheimer Society of Canada, Womens Brain Health Initiative, Picov Family Foundation, New Brunswick Health Research Foundation, Ontario Brain Institute.	
3	Royalties or licenses	None None	
4	Consulting fees	None Honoraria for Advisory boards for Eisai, Lilly	Payments to the institution and to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Scientific Director of the Canadian Consortium on Neurodegeneration in Aging, unpaid	
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
$[\boxtimes]$	oxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	12/10/2023
Your Name:	PAQUET CLAIRE
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/29/2023
Your Name:	Verna Porter, MD
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/28/2023
Your Name:	Craig Ritchie
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Helios Medical Communications	Medical writing Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Biogen Roche Diagnostics Lilly Merck	Clinical Trial Contract to Institution
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Biogen Lilly Merck Actinogen Roche Diagnostics	To my company
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Lilly	Speaker Fee to My Company
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Lilly	To attend Alzheimers Europe meeting in Helsinki
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	DSMB for UCL sponsored trial: Despiad	Non-commercial and no fee
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Majority Share Holder and Founder	Brain Health Scotland: Life Sciences
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	12/16/2023
Your Name:	Sietske A.M. Sikkes
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Health~Holland, Topsector Life Sciences & Health (PPP-allowance; LSHM19051; LSHM20084; LSHM22026 SGF) ZonMW (#10510032120003, #7330502051 and #73305095008) Ministery of Health, Welfare and Sports (#90001586)	Payments made to the institution Payments made to the institution Payments made to the institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
3	Royalties or licenses	□ None		
		Brain research center (license fees)	Payments made to the institution	
		Green Valley	Payments made to the institution	
		VtV Therapeutics	Payments made to the institution	
		Alzheon	Payments made to the institution	
		Vivoryon	Payments made to the institution	
		Roche	Payments made to the institution	
		Toyama	Payments made to the institution	
4	Consulting fees	□ None		
		Biogen	Payments made to the institution	
		Prothena Biosciences	Payments made to the institution	
		AriBio Co, LTD	Payments made to the institution	
5	Payment or honoraria for	□ None		
	lectures, presentations, speakers	Bohn Stafleu van Loghum (conference presentation)	Payments made to the institution	
	bureaus,			
	manuscript			
writing or				
	educational			
	events			
6	Payment for expert testimony	⊠ None		
7 Support for attending None				
	meetings and/or	Alzheimer's Association	Payments made to the institution	
	travel			
8	Patents planned,	⊠ None		
	issued or			
	pending			
9	Participation on a Data Safety	□ None		
	Monitoring	Cogstate LTD Scientific Advisory Board	Payments made to the institution	
	Board or		,	
	Advisory Board			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	AAIC Progam Committee	Unpaid
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	□ None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	November 29, 2023
Your Name:	Michael R Smith
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	12/5/2023
Your Name:	Christina Marsica Grassi MD
Manuscript Title:	Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset
Manuscript Number (if known):	ADJ-D-23-00856

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None Biogen		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	Former employee Biogen (compensation—2020-2023)		
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:			11/28/2023			
Your Name:			Ivana Rubino			
Manuscript Title:			Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset			
Mar	nuscript Number (if l	known):	ADJ-D-23-00856			
conf affe indi	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if					
-	medication is not m	-		acturers of antinypertensive medication, even in		
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	No	one	Click the tab key to add additional rows.		
			Time frame: past 36 month	s		
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] No	one			
3	Royalties or licenses	⊠ No	one			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Biogen employee	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	Biogen Stockholder		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	Full time employee of Biogen Inc.		
Please place an "X" next to the following statement to indicate your agreement:				
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			